International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8330407
Original Article
To Study Lipoprotein (A) As Risk Factor for Acute Ischaemic Stroke
 ,
Published
Aug. 31, 2023
Abstract

Background: Traditional cardiovascular risk factors, such as age, male sex, hypertension, diabetes mellitus, atrial fibrillation, and dyslipidemia, are associated with ischemic stroke. However, a significant fraction of strokes is still considered to be cryptogenic. Cryptogenic strokes make up roughly 40% of all ischemic stroke cases among stroke patients under the age of 55, highlighting the potential significance of additional, probably unidentified risk factors.

Objectives: To study the significance of lipoprotein (a) as a risk factor for acute ischaemic stroke with its levels in patients of different ages and sex.

Design: single center, cross-sectional, open hospital-based, observational study

Material Methods: 100 patients with acute ischaemic stroke taken who were >18 years of age and s. lipoprotein(a) levels were done. These levels were correlated with age, gender, and conventional risk factors like hypertension, smoking, and diabetes.

Results: In our study out of 100 81% of patients had abnormal lipoprotein(a) levels. The mean lp(a) levels were more in the younger age group [<55yr is 53.34 + 24.06 mg/dl and in >55yr is 45.93 + 24.19 mg/dl] and male sex but they were statistically insignificant.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
1282 Views
481 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved